The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

10 Aug 2021 07:00

RNS Number : 0791I
MaxCyte, Inc.
10 August 2021
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options

Gaithersburg, Maryland - 10 August 2021: MaxCyte  (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, announces that on 9 August 2021, options of common stock in the Company ("Common Stock") were granted equally to all Company employees, including 100,000 options granted to PDMRs who are directors or officers of the Company ("PDMR Option Grants"). Details of the PDMR Option Grants are given below:

 

Grants to PDMRs

 

Doerfler, Doug

10,000

Thompson, J. Stark

10,000

Mandell, Art

10,000

Erck, Stan

10,000

Brooke, Will

10,000

Johnston, John

10,000

Douglas, Richard

10,000

Hemrajani, Rekha

10,000

Al-Wakeel, Yasir

10,000

Murphy, Amanda

10,000

Total

100,000

 

 

All option grants vest over 4 years. 1/4th of the grants vest 1 year following the date of the grant, with the remainder of the options vesting ratably monthly in 36 monthly installments thereafter. The options have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 9 August 2021, of $16.63

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Doug Doerfler

2

Reason for the notification

a)

Position/status

Chief Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

J. Stark Thompson

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Art Mandell

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Stan Erck

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Will Brooke

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

John Johnston

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Douglas

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Rekha Hemrajani

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Yasir Al-Wakeel

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Amanda Murphy

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

MaxCyte Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black / Duncan Monteith / Matthew O'Dowd

 

 

+44 (0)20 7260 1000

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams

 

 

+44 (0)20 7710 7600

 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

+1 415-937-5400

 ir@maxcyte.com

 

US Media Relations

Jamie Lacey-Moreira

PressComm PR, LLC

 

+1 410-299-3310

jamielacey@presscommpr.com

 

 

 

 

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAFPNELEFEAA
Date   Source Headline
11th Jun 20187:00 amRNSMaxCyte & NIH enter CRADA for Sickle Cell Disease
21st May 20187:00 amRNSPreclinical Results at ASGCT Annual Meeting
30th Apr 20187:00 amRNSNotice of AGM and Annual Report
25th Apr 20187:00 amRNSCMO Appointment
4th Apr 20187:00 amRNSFinal Results for Year Ended 31 December 2017
15th Mar 20187:00 amRNSNotice of Full Year Results
28th Feb 20185:00 pmRNSDirector/PDMR Shareholding
15th Feb 20187:00 amRNSGrant of Options
13th Feb 20187:00 amRNSDr Richard Douglas Joins MaxCyte Board
1st Feb 20184:06 pmRNSBlock listing Interim Review
23rd Jan 20181:32 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSTrading Update
12th Jan 20185:13 pmRNSTotal Voting Rights
30th Nov 20173:26 pmRNSTotal Voting Rights
31st Oct 201712:47 pmRNSResult of AGM
16th Oct 20177:00 amRNSDeclaration of Audit Remuneration
5th Oct 20176:32 pmRNSHolding(s) in Company
5th Oct 20176:31 pmRNSHolding(s) in Company
28th Sep 20175:15 pmRNSNotice of AGM
19th Sep 20177:00 amRNSInterim Results
25th Aug 20177:00 amRNSNotice of Half Year Results
20th Jul 20176:02 pmRNSGrant of Options
12th Jul 20177:00 amRNSTrading Update
6th Jun 20177:00 amRNSResearch & Development Agreement with NIAID
31st May 20174:30 pmRNSTotal Voting Rights
2nd May 20171:42 pmRNSBlock Listing Application
25th Apr 20176:27 pmRNSHolding(s) in Company
25th Apr 20177:00 amRNSPresentation of Positive Preclinical Data
20th Apr 20176:00 pmRNSResult of Special Meeting and Issue of Equity
13th Apr 20171:00 pmRNSNotice of AGM and 2016 Annual Report and Accounts
31st Mar 201712:40 pmRNSResults of Placing
31st Mar 20177:00 amRNSProposed Placing to raise up to approx. £20.0m
20th Mar 20177:00 amRNSFull Year Results
14th Mar 20177:00 amRNSCRISPR THERAPEUTICS/CASEBIA COMMERCIAL LICENSE
2nd Mar 20177:00 amRNSMaxCyte to Present Pre-Clinical CARMA Data at AACR
1st Mar 20177:00 amRNSNotice of Full Year Results
24th Jan 20177:00 amRNSTrading Update
12th Jan 20177:00 amRNSStudy Published in Science Translational Medicine
3rd Jan 20172:49 pmRNSIssue of Equity from exercise of Share Options
21st Dec 20167:00 amRNSMaxCyte Announces Collaboration to Advance CARMA
6th Dec 20169:34 amRNSIssue of Equity from exercise of Share Options
27th Oct 20167:00 amRNSResult of Annual General Meeting
21st Oct 20167:43 amRNSDirector/PDMR Shareholding
28th Sep 20166:00 pmRNSGrant of Options
27th Sep 20167:00 amRNSFinancial Results for Six Months ended 30 June 16
19th Sep 20165:00 pmRNSNotice of AGM
6th Sep 20167:00 amRNSMaxCyte Bolsters Distributor Network in Asia
6th Sep 20167:00 amRNSNotice of Interim Results
12th Jul 20167:00 amRNSTrading Update
14th Jun 20167:00 amRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.